Novavax Inc (NVAX) — closed signal from May 5, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on August 3, 2026.
Predicted vs. what happened
NVAX price · publication thesis → realized outcomesplit-adjusted
$7.50 – $8.20Entry zone — fair-value band
$8.09Published — price the day we called it
$10.36Target — the price the thesis aimed for
$11.61Peak — highest point inside the window, not a realized return
$7.41Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 3 days.
Peak price
$11.61
peak on May 27, 2026 — not a realized returnPeak gain
+43.4%
peak, from the publication priceWindow close
$7.41
end-of-window price, context onlyDays to target
3
Window
May 5, 2026 – August 3, 2026
The thesis — published May 5, 2026
Predicted growth
+28%
over the measurement windowTarget price
$10.36
the price the thesis aimed forEntry zone
$7.50 – $8.20
the fair-value band we waited forPrice at publication
$8.09
published May 5, 2026Confidence
69%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Novavax's recent shift toward licensing and partnerships with big drugmakers gives a clear chance for big upside if vaccine data and upcoming earnings go well. The company has cash and looks reasonably valued, but biotech results and heavy short interest make outcomes very uncertain. Near-term results are speculative and likely to cause big price swings.
Primary drivers
- Licensing deals could make revenue steadier and more reliable
- Deals with Sanofi and Pfizer boost credibility and reach
- Earnings and vaccine trial updates can move the stock quickly
- Cash on hand reduces the chance of forced financing
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.